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Purpose: To build a statistical model to quantitatively correlate the anatomic features of structures
and the corresponding dose-volume histogram (DVH) of head and neck (HN) Tomotherapy (Tomo)
plans. To study if the model built upon one intensity modulated radiation therapy (IMRT) technique
(such as conventional Linac) can be used to predict anticipated organs-at-risk (OAR) DVH of patients
treated with a different IMRT technique (such as Tomo). To study if the model built upon the clinical
experience of one institution can be used to aid IMRT planning for another institution.
Methods: Forty-four Tomotherapy intensity modulate radiotherapy plans of HN cases (Tomo-IMRT)
from Institution A were included in the study. A different patient group of 53 HN fixed gantry IMRT
(FG-IMRT) plans was selected from Institution B. The analyzed OARs included the parotid, larynx,
spinal cord, brainstem, and submandibular gland. Two major groups of anatomical features were
considered: the volumetric information and the spatial information. The volume information includes
the volume of target, OAR, and overlapped volume between target and OAR. The spatial informa-
tion of OARs relative to PTVs was represented by the distance-to-target histogram (DTH). Important
anatomical and dosimetric features were extracted from DTH and DVH by principal component anal-
ysis. Two regression models, one for Tomotherapy plan and one for IMRT plan, were built indepen-
dently. The accuracy of intratreatment-modality model prediction was validated by a leave one out
cross-validation method. The intertechnique and interinstitution validations were performed by using
the FG-IMRT model to predict the OAR dosimetry of Tomo-IMRT plans. The dosimetry of OARs,
under the same and different institutional preferences, was analyzed to examine the correlation be-
tween the model prediction and planning protocol.
Results: Significant patient anatomical factors contributing to OAR dose sparing in HN Tomother-
apy plans have been analyzed and identified. For all the OARs, the discrepancies of dose indices
between the model predicted values and the actual plan values were within 2.1%. Similar results
were obtained from the modeling of FG-IMRT plans. The parotid gland was spared in a comparable
fashion during the treatment planning of two institutions. The model based on FG-IMRT plans was
found to predict the median dose of the parotid of Tomotherapy plans quite well, with a mean error of
2.6%. Predictions from the FG-IMRT model suggested the median dose of the larynx, median dose of
the brainstem and D2 of the brainstem could be reduced by 10.5%, 12.8%, and 20.4%, respectively,
in the Tomo-IMRT plans. This was found to be correlated to the institutional differences in OAR
constraint settings. Re-planning of six Tomotherapy patients confirmed the potential of optimization
improvement predicted by the FG-IMRT model was correct.
Conclusions: The authors established a mathematical model to correlate the anatomical features
and dosimetric indexes of OARs of HN patients in Tomotherapy plans. The model can be used
for the setup of patient-specific OAR dose sparing goals and quality control of planning results.
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The institutional clinical experience was incorporated into the model which allows the model from
one institution to generate a reference plan for another institution, or another IMRT technique.
© 2013 American Association of Physicists in Medicine. [http://dx.doi.org/10.1118/1.4828788]
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1. INTRODUCTION
Intensity modulated radiation therapy (IMRT) has provided
us with the ability to spare the surrounding critical organs-
at-risk (OAR) while achieving prescription coverage to the
planning target volume (PTV).1–3 Although IMRT planning
has become more intelligent and automatic,4–6 the input of the
planners is still the essential driving force for the quality of the
plan. One major difficulty of IMRT planning is the unknown
feature of best achievable dosimetry at the beginning of opti-
mization. Currently a more optimal plan normally requires the
diligent effort of trial and error of the planner to guide the op-
timization manually. Therefore the quality of the IMRT plan
depends highly on the experience of the planner, time avail-
able for the case and institutional/individual dose constraints
set by physicians. While quality assurance (QA) has become
a main concern in the field of radiation therapy, the QA pro-
cess of IMRT plans normally only checks the agreement be-
tween the directive of physician and the treatment plan, and
between the calculated results by computer and measured re-
sults on the Linac. The dosimetry of a new plan can be com-
pared with a standard protocol, but it cannot be verified for a
particular patient whether the plan is as optimal as other plans
or not.
It has become an important topic to quantify the geo-
metrical distribution of organs and the ability of dosimetric
avoidance of IMRT plans.5, 7–9 For example, in a study of
the dose sparing of parotid glands for head-and-neck (HN)
cancer patients, Hunt et al. found that percent gland volume
overlapping with PTV could predict the mean gland dose.7
In prostate cancer cases, Reddy et al. reported that the mean
dose to rectum and bladder increased with increasing prostate
volume.8 Moore et al. demonstrated a correlation between
the fraction of OAR volume overlapping with PTV and the
OAR mean dose, and used the correlation to formulate a tool
of quality control for the IMRT plans.9 Further, Zhu et al.
proposed the concept of distance-to-target histogram (DTH)
to establish the correlation between the OAR-PTV anatomy
and OAR dose-volume histograms (DVHs).10 Wu and his
colleagues constructed a database with target-OAR overlap
volume histogram (OVH) and DVH information of 91 HN
patients.11 From the OVH analysis, the initial planning goals
for IMRT optimization were generated from the OVH analy-
sis of the database. Recently, Yuan et al. analyzed a database
of high-quality prior plans including 64 prostate and 82 HN
cases.12 They quantified the effects of an array of patient
anatomical features of the PTV and OARs and their spa-
tial relationships on the interpatient OAR dose sparing vari-
ation in IMRT. This evidence-based model was able to reli-
ably predict OAR dose sparing that was achievable based on
the best available prior experience. The concept of “refined
model” was introduced by Appenzoller et al. to exclude the
outliers indicated by the “average model” from the training
cohort of all patients.13 The suboptimal plans were correctly
identified by the model which guided the replanning with bet-
ter OAR sparing achieved afterwards.
In these previous studies, all IMRT techniques used in
modeling were the fixed gantry IMRT (FG-IMRT). Further,
all the data used for modeling and validation were from the
same institution and from the same patient group. Tomother-
apy provides another way of intensity modulation and in the-
ory can produce better dose distributions than static gantry
IMRT for complex cases.14 However, there is no published
work to analyze the correlations between the anatomy and
achieved dosimetry for Tomotherapy patients. The commonly
used simultaneous integrated boost (SIB) treatment scheme
of Tomotherapy also poses special difficulty of modeling the
anatomy and dosimetry relations.13 While a few publications
have demonstrated that a well-established model can predict
the DVH of a new patient treated by the same technique,9–11
it is unknown whether the model is still valid when it is ap-
plied to another IMRT treatment modality. The planning pro-
cess is normally governed by the institutional guidelines, and
the quality of the plan is inevitably affected since the guide-
lines are often used as the objectives for which the planner
strives. It has been found that the plan quality of IMRT was
inconsistent among institutions.15–17 Further, the training of
model based on high quality plans to correlate the anatomic
features and optimized dosimetry of structures naturally in-
corporates the best clinical experience of an institution. It is
unclear how the experience of one institution can benefit the
treatment planning of another institution which employs dif-
ferent protocols and planning approaches.
In this paper, we extended our previous work of quanti-
tative analysis of the factors affecting the organ-at-risk dose
sparing of FG-IMRT planning12 to Tomotherapy planning.
We applied our model built on the FG-IMRT plans of HN
patients treated at Institution B to predict the dosimetry of
Tomotherapy plans of patients treated at Institution A. The
predicted and actual DVHs of all structures were compared.
In this way, we investigated the extent to which a model’s de-
pendence on a particular IMRT treatment technique and the
clinical experience of institutions with different protocols can
be useful to each other.
2. METHODS AND MATERIALS
2.A. Patient treatment plans
Forty-four former Tomotherapy HN plans with concurrent
boost were included in the study. These plans were randomly
selected from the clinical plans used for patient treatment at
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TABLE I. Template of OAR dose constraints for HN Tomotherapy planning in Institution A and range of OAR
dose constraints for HN FG-IMRT planning in Institution B (Institution B specifies the constrict of patient case
by case.).
Anatomic structures Institution A (Tomotherapy) Institution B (FG-IMRT)
Brainstem Max: 54 Gy to point dose Max: 25–35 Gy
Spinal cord Max: 50 Gy to point dose Max: 40–45 Gy
Larynx Mean dose ≤ 41 Gy Median dose: 15–30 Gy
Volume receiving 60 Gy ≤ 24%
Parotid Mean dose < 26 Gy Median dose: 5–26 Gy
50% receives < 30 Gy
Submandibular Mean dose < 35 Gy Median dose: < 30 Gy
Oral cavity Mean dose < 39 Gy Median dose: 10–40 Gy
Cochlea Mean dose < 45 Gy Max dose 30–45 Gy
Unspecified tissue outside of PTV ≤1% receives > 110% of the Rx ≤1% receives > 110% of the Rx
Institution A. The primary target dose was 54–60 Gy and
the boost target dose was 60–70 Gy. Tomotherapy delivery
was on a TomoTherapy HD machine (Accuray) in helical
mode with simultaneous table translation and gantry rotation.
Beams were 6 MV and distributed evenly from 51 directions.
The modulation factor used was 0.287–0.35, pitch 2.6–3.5,
and longitudinal field width 2.5 cm. Leaf width was 6.25 mm
at the isoplane (SAD 85 cm). Beamlet calculation was car-
ried out prior to the optimization to accelerate the dose cal-
culation during each iteration of optimization. The beam-on
time of average HN treatment was 7–10 min. Treatment plan-
ning was performed with TomoTherapy planning software
(TomoHD 1.2.1, Accuray) under the guidance of an insti-
tutional prescription and OAR sparing template, as listed in
Table I. When training the DVH model for an OAR, only the
cases in which the OAR dose sparing satisfied the institutional
template were used.
Fifty-three FG-IMRT HN plans were retrospectively an-
alyzed. These plans were randomly selected from the clini-
cal plans performed at Institution B. All patients were treated
in sequential boost fashion. The prescription was 44 Gy or
50 Gy to the primary PTV and 70 Gy to boost PTV. Nine
equally spaced coplanar 6 MV beams were used. Leaf width
was 5 mm at the isoplane (SAD 100 cm). Treatment was
delivered on Varian Trilogy and 2100EX linear accelerator
with treatment time 6–10 min. Planning was performed with
Eclipse Version 10.0 (Varian). Institution B does not use a
default dose constraint protocol for HN IMRT planning. In-
stead, the dose constraints were prescribed case by case by
the physicians and they were tighter than The Radiation Ther-
apy Oncology Group (RTOG) guidelines.18 The ranges of the
dose constraints for major OARs are listed in Table I. The
training set for an OAR DVH model did not include the cases
in which there is no physician prescription for such OAR or
the cases in which the OAR dose sparing did not meet the
physician’s prescription.
The primary tumor sites of two patient groups were similar
including oropharynx, base of tongue, tonsil, laryngopharynx,
and nasopharynx. The modeled OARs included the parotid,
brain stem, spinal cord, larynx, and submandibular gland
(SMG). The model prediction and actual results of the parotid,
brainstem, and larynx were presented in detail. The institu-
tional review boards of two institutions approved this patient
study involving de-identified retrospective data.
2.B. Anatomical features and correlation model
An array of anatomical features was analyzed to study
their contributions to OAR dose sparing. The OARs and
their anatomical features analyzed for this study are listed in
Table II. The distance to target histogram (DTH) encodes the
spatial relationship between the OARs and the PTV.10 When
the Euclidean form of the distance function is used, DTH is
equivalent to overlap volume histogram (OVH) defined by Wu
et al.5 In the Euclidean space, DTH at a distance d is calcu-
lated as the fraction of OAR volume with its maximum dis-
tance to the PTV surface (SPTV) less than d. The distance func-
tion r from an OAR voxel viOAR to the PTV surface is defined





{∥∥viOAR − vkPT V
∥∥ ∣∣vkPT V ∈ SPT V
}
.
In the actual implementation, two modifications to the Eu-
clidean distance are made in order to account for the in-
creased dose fall-off rate for the voxels outside the primary
treatment fields (out-of-field) and to account for the slower
dose fall-off in the regions far away from the PTV. Princi-
pal component analysis (PCA) tool is widely used to iden-
tify the features hidden in high dimension data.10, 19 For
TABLE II. Anatomical and dosimetric features considered in the Tomother-
apy models.
Anatomical and dosimetric features
Distance to primary and boost target histogram (DTH)
OAR volumes
Primary and boost PTV volume
Fraction of OAR volume overlapping with PTVs (overlap volume)
Fraction of OAR volume outside the treatment fields (out-of-field volume)
Dose prescription to the primary and boost PTVs
Primary PTV D95
Boost PTV dose homogeneity (D2-D99)
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instance the first order of PC is related to the mean of the
histogram and the second order is related to the dominant
gradient within a range. Similar to our previous study,10 we
used the first three principal components to quantitatively
characterize the DVH and DTH curves with greatly reduced
dimensions. The correlation between the principal compo-
nents of DVH and patient anatomical features was obtained
by a stepwise multiple regression method. The stepwise re-
gression method includes multiple related anatomical factors
in the beginning and then eliminates the least significant one
at each step of regression during the process of modeling. The
significance factors were identified with p-value < 0.05. The
details of anatomical factors and modeling of FG-IMRT plan-
ning were described in previous studies.10, 12
2.C. Model validation
The validation of models includes three parts. (1) Intra-
patient group: The model was trained using all the patients in
the database of the same group except the test case (leave-one-
out). The OAR DVH of the validation case was predicted by
the model and compared with the actual plan DVH. The dosi-
metric parameters such as the median dose were computed
from the modeled DVHs and then compared with the DVHs
of the actual plan. (2) Intertechnique: At this step, we studied
the effect of treatment modality by fixing the clinical objec-
tive first. The parotid was used as an example OAR since a
similar constraint was adopted by two institutions in their re-
spective FG-IMRT and Tomotherapy planning. The parotid
DVH models trained with the FG-IMRT plans were applied
to the Tomotherapy cases. The predicted DVHs by the FG-
IMRT models were compared with the actual curves of To-
motherapy plans in a leave-one-out fashion. (3) Interinstitu-
tional planning protocol comparison: After the previous step
of intertechnique study, we changed the clinical objective us-
ing the larynx (a parallel structure) and brainstem (a serial
structure) as the examples. Two institutions have very differ-
ent dosimetric requirements of the brainstem and larynx and
consequently may result in different planning efforts as well
as dose sparing. The FG-IMRT model predicted and actual
Tomotherapy plan dosimetric endpoints of these two struc-
tures were compared. In all the comparisons for model valida-
tion, a 10% of target prescription dose value (7 Gy) is defined
as the error bound.
3. RESULTS
3.A. Factors of interpatient variation
in the training dataset
We have modeled the OAR DVHs for the parotid, lar-
ynx, spinal cord, brainstem, and SMG in the Tomotherapy
plans. An array of anatomical features was screened for in-
dividual OARs, respectively. The combination of these fac-
tors had strong correlation with the DVH PCS1 (1st of the
three most significant principle components) of all OARs. The
multiple determination coefficients ranged from 0.63 to 0.88.
DVH PCS2 (2nd of the three most significant principle com-
ponents) of OARs except cord and larynx also showed high
combined coefficients with the significant anatomical factors
(0.60–0.78). We expanded our previous modeling work of
FG-IMRT to include more OARs of the HN region.12 Simi-
lar patterns of correlation were found in the FG-IMRT model
and the Tomotherapy model.
3.B. Accuracy of model prediction
within patient group
The DVHs of the parotid, larynx, spinal cord, brainstem,
and SMG for Tomotherapy plans were calculated by the mul-
tiple regression model in a leave-one-out fashion. The model-
predicted DVHs were compared to their corresponding DVHs
in the actual plans to assess the effectiveness of the model.
The comparison of the parotid DVH for a sample case is
shown in Fig. 1(a). The Tomotherapy-based-model predicted
DVH (solid red curve with maximum dose 55 Gy) was a good
FIG. 1. Comparison of model predicted DVH and actual DVH of the parotid
of a sample clinical case. (a) Tomotherapy model (solid red curve with max-
imum dose 55 Gy) and actual DVH of a Tomotherapy plan. (solid blue curve
with maximum dose 59 Gy) (b) FG-IMRT model (solid red curve with maxi-
mum dose 70 Gy) and actual DVH of a FG-IMRT plan (solid blue curve with
maximum dose 73 Gy).
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FIG. 2. Correlation of model predicted parotid median dose with actual clin-
ical values. (a) Tomotherapy model vs clinical values for Tomotherapy cases.
(b) FG-IMRT model vs clinical values for FG-IMRT cases.
estimate of actual DVH of Tomotherapy plan (solid blue curve
with maximum dose 59 Gy). Figure 2(a) shows the correla-
tion of model predicted parotid median dose with actual clin-
ical values for the parotids in all the Tomotherapy cases. The
differences between the modeled median dose values and the
clinical values were within 10% error bound in 33 of the 37
parotids. The difference of the median dose between the pre-
dicted and actual plans was 1.5% on average, with the max-
imum positive deviation of 8.5% and negative deviation of
18.4%.
For the FG-IMRT dataset, the predicted OAR DVHs gen-
erated by the FG-IMRT model were also compared with the
actual plan DVHs in a leave-one-out fashion. Consistent with
our finding in Tomotherapy study, in most of the plans the
predicted and actual plan DVHs were well matched. The mod-
eled and the actual parotid DVH for a sample case are shown
in Fig. 1(b). The differences between the modeled median
dose values and the clinical values for 46 out of 52 parotids
were within 10% error bound [Fig. 2(b)]. The difference of the
median dose between the predicted and actual plans was 0.9%
on average, with the maximum positive deviation of 15.3%
and negative deviation of 17.7%.
3.C. Accuracy of model prediction across
treatment modalities
The parotid was spared in a similar way by both institu-
tions. When the parotid overlapped the PTV, the coverage
of target often took the priority. The hot spot was usually
excluded in the overlapped area. The mean dose and vol-
ume of low dose area of parotid were optimized as low as
possible. In this way, the overall curve of parotid DVH was
driven similarly in plans designed by two institutions, regard-
less of IMRT techniques. Using the model built for the FG-
IMRT patients, we predicted the DVHs of the parotid of To-
motherapy patients. In Fig. 3, we showed the results from
one sample patient (a) to a group of patients (b) and statis-
tical results (c). Figure 3(a) shows FG-IMRT model predicted
DVHs (dashed red curve with maximum dose 50 Gy), To-
motherapy model predicted DVHs (solid red curve with max-
imum dose 55 Gy) and actual clinical plan DVHs (solid blue
curve with maximum dose 59 Gy) of a sample Tomotherapy
patient. The model based on FG-IMRT plans was found to
predict the median dose of the parotid of Tomo-IMRT plans
very well, with a mean error of 2.6%, close to the mean
error of 1.5% for intratomotherapy prediction. The maxi-
mum deviation ranged from −13.8% to 10.7%. Compared
with the clinical values, the median dose predicted for the
Tomotherapy cases by the FG-IMRT models for 34 out of
37 parotids were within 10% error bound of [Fig. 3(b)].The
distribution of parotid median dose difference between:
(1) IMRT model prediction and Tomotherapy plan value,
(2) Tomotherapy model prediction and Tomotherapy plan
value, and (3) IMRT model prediction and IMRT plan value
are compared in Fig. 3(c) using box plots. All mean differ-
ences were small within about 3%. The p-value for a Kruskal
Wallis test is 0.75, indicating the differences of the median
values of the distributions were not significant. This suggests
that the parotid model trained on a patient group treated with
one IMRT technique can predict the median dose (and pos-
sibly the entire DVH) in another patient group treated with
a different IMRT modality. We confirmed this finding with
another critical structure, the spinal cord, which was spared
similarly between two institutions. The mean difference of D2
(dose of 2% volume) of the spinal cord is −2.0% between the
IMRT model prediction and Tomotherapy plan value, 1.3%
between the Tomotherapy model prediction and Tomotherapy
plan value, and −1.7% between the IMRT model prediction
and IMRT plan value. The results of the spinal cord agree with
those of the parotid.
3.D. Accuracy of model prediction across
planning protocols
Besides the technical differences, in order to further study
whether a model built at one institution can be used as a refer-
ence at another institution with different protocols, we applied
the FG-IMRT model to predict the dose of the larynx and
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FIG. 3. Comparison of dosimetry of the parotid of actual Tomotherapy plan
and predicted values by two models. (a) Comparison of DVH of an actual To-
motherapy plan (solid blue curve with maximum dose 59 Gy) and predicted
DVHs by Tomotherapy model (solid red curve with maximum dose 55 Gy)
and FG-IMRT model (dashed red curve with maximum dose 50 Gy). (b) Cor-
relation of the parotid median dose of actual Tomotherapy plans in the study
group vs Tomotherapy model and FG-IMRT model. (c) Deviations of the pre-
dicted parotid median dose by the FG-IMRT model and Tomotherapy model
from the actual values of Tomotherapy or FG-IMRT plan. The hormonal red
line inside box is the mean value. The blue box represents the interquartile
range (IQR) from 25% quartile to 75% quartile. The red cross indicates the
outlier which is defined as the points more than 1.5 times IQR away from
the box edge. The black dashed lines connect the box with the most extreme
values which are not outliers.
brainstem of Tomotherapy plans. During the Tomotherapy
planning, the larynx mean dose (≤41 Gy) and V60 (≤24%)
were two main objectives of dose restrictions. Since the lar-
ynx often had overlap with the primary PTV, the DVH points
penalized were often chosen in the low dose region for main-
taining target coverage. With FG-IMRT planning, the opti-
mizer was in general pushed harder in sparing the larynx.
Although there was no general template used for FG-IMRT,
the expected median dose value based on experience was
15–30 Gy, which was much lower than the default objective
in the Tomotherapy planning template. The median dose of
model prediction and actual plan is compared in Fig. 4(a).
When the respective model was used, there was a small dif-
ference between the predicted and actual plan value of the
median dose (Tomo model 2.1%; FG-IMRT model 1.9%).
However, when the FG-IMRT model was used to estimate
the median dose of the larynx of Tomotherapy patients, the
projected result was 10.5% lower than the actual value of
the clinical plan. The FG-IMRT model suggests possible bet-
ter sparing of the larynx of Tomotherapy plans, which is
consistent with the stricter constraint used in the FG-IMRT
optimization.
The brainstem was planned differently in two institutions
as well. The major constraint used in Tomotherapy plan-
ning was to limit the maximum point dose to less than
54 Gy. FG-IMRT planning varies the goal according to the
individual patient with the typical maximum dose set to
25–35 Gy. In addition, low dose volume was pushed to be
as small as possible such as to spare the overall volume.
Two dosimetric endpoints, D2 and median dose were se-
lected to assess the difference of model prediction and actual
value. Similar to the parotid and larynx reported previously,
the model established on the same patient group in gen-
eral predicts well the actual D2 [Fig. 4(b)] and median dose
[Fig. 4(c)]. If the FG-IMRT model was used to predict the
D2 of Tomotherapy patients, the difference (FG-IMRT Model
– Tomotherapy Plan) was −20.4% [Fig. 4(b)]. The median
dose predicted by the FG-IMRT model was 12.8% lower than
the actual Tomotherapy plan value [Fig. 4(c)]. The difference
found in the dosimetry index agrees largely with the different
degree of strictness of constraint goals used in planning.
To further illustrate the possibility that models built at one
institution can accurately portray protocol differences at an-
other institution, we re-generated Tomotherapy plans for three
patients with the maximum deviation of larynx dosimetry
and three patients with the maximum deviation of brainstem
dosimetry between the original Tomotherapy plan and FG-
IMRT model prediction (Fig. 5). (The Tomo model prediction
and actual value are similar.) The FG-IMRT model calculated
DVHs were used as the objective to improve the dosimetry
of the larynx and brainstem during replanning, while the tar-
get coverage and the sparing of other OARs were kept sim-
ilarly. With the FG-IMRT model predicted value as the ref-
erence, we compared dosimetric endpoints of larynx median
dose, brainstem D2 and brainstem median dose in the origi-
nal and re-optimized Tomotherapy plans. From these extreme
cases, replanning lowered the larynx median dose from on av-
erage 33.8 to 20.6 Gy, while the FG-IMRT model prediction is
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FIG. 4. Deviations of the predicted dosimetric endpoints by the FG-IMRT
model and Tomotherapy model from the actual values of Tomotherapy or
FG-IMRT plan. (a) larynx median dose (b) brainstem D2 and (c) brainstem
median dose. The hormonal red line inside box is the mean value. The blue
box represents the interquartile range (IQR) from 25% quartile to 75% quar-
tile. The red crosses indicate the outlier which is defined as the points more
than 1.5 times IQR away from the box edge. The black dashed lines connect
the box with the most extreme values which are not outliers.
21.7 Gy on average. Similarly, brainstem D2 was reduced
from 35.9 to 22.7 Gy with model prediction value 22.0 Gy.
The brainstem median dose was also lowered from 23.5 to
10.7 Gy which is even lower than the model predicted value
FIG. 5. Dosimetric endpoints of six Tomotherapy extreme cases replanned
with the guide of the FG-IMRT model.
14.7 Gy. Please note in the original TomoTherapy planning,
these dosimetric end points were in general not optimized.
Replanning was found to have no noticeable effect on the dose
of other OARs. The compromise of PTV coverage is very
slight, from 96.9% to 96.3%. Although the FG-IMRT model
was established based on its own patient group, planning pro-
tocol, and treatment technique, it proves useful in guiding the
Tomotherapy planning of a completely different patient
group.
4. DISCUSSION
From practice we know radiotherapy treatment planning
involves two sets of information. One set is the anatomy in-
cluding volume, shape and location of structures. The other
set is the dosimetry and it is determined by multiple fac-
tors such as the anatomy, constraints and experience of the
planner. Our modeling correlates these two sets of variables
quantitatively. The experimental results of Tomotherapy and
FG-IMRT cases showed the actual planed values could be
predicted by its respective model. Therefore we believe two
models are accurate and both describe the relations between
the key features of anatomy and key properties of dosime-
try of real clinical plans. Furthermore, the FG-IMRT model
was able to estimate the dosimetry of the parotid planned in
a similar way but treated with Tomotherapy. This implies a
model built upon one IMRT technique may be generalized to
some different techniques with similar theoretical underpin-
ning. This will benefit the quality control of the implementa-
tion of a new IMRT technique because the model built on a
traditional technique can provide reference dosimetry for the
new technique as long as the constraint is similar. When the
FG-IMRT model was applied to study the larynx and brain-
stem of Tomotherapy patients, model estimated the dosimetric
values (such as median dose and D2) of clinical plans could
be further reduced by 10%–20%. This is largely in agreement
with the different constraints used in two types of treatment
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planning. The replanning of six Tomotherapy cases with ex-
treme deviations confirmed the prediction of the FG-IMRT
model was useful in guiding the effort of further sparing the
larynx and brainstem in spite of different patient groups and
IMRT techniques used.
The application of this work may help the implementa-
tion of automated IMRT planning and qualitative quality con-
trol of plan dosimetry. The knowledge driven autoplanning
approach allows the prediction of dosimetry of a new plan
by an anatomy-dosimetry correlation model built upon previ-
ously executed treatment plans5, 9, 10 The model presents the
planner the anticipated DVH of a new case based on the pre-
vious experience prior to the treatment planning. This can be
a very useful tool in helping the design of dosimetric opti-
mizer parameters and tells planner whether it is an appropri-
ate time to stop the iterations of optimization. However more
effort is planned in our future work to make the optimization
process automatic. It has been found from our clinical expe-
rience that the optimized result could be different for some
cases when setting up the optimizer once or gradually adjust-
ing the parameters, although the final parameters of the two
methods are the same. Field width, pitch value, and modula-
tion factor are another set of Tomotherapy planning parame-
ters which may be modeled from a library of previous expe-
rience of planning results in our future work. We also want
to stress that the use of model prediction does not necessarily
generate better dosimetry than using a general dosimetry goal
sheet. We can imagine when a highly experienced planner has
a great amount of extra time to improve a plan even after all
constraints of the goal sheet have been met, this plan may ex-
ceed the average plans made within the time limit of normal
clinical workflow. The typical clinical plans were used in our
modeling work such that model prediction reflects the realis-
tic prior clinical experience and suggests best practice goals
based on available evidence.
Similar to the IMRT on conventional Linac, current QA
of Tomotherapy usually includes two components: (1) chart
check to verify the agreement between physician directive and
plan reported values and (2) phantom irradiation to compare
the calculated and delivered dose. The checking of the qual-
ity of dosimetry itself always counts on the experience of an
individual and often turns out to be inconclusive. For patients
with complicated anatomy, it is almost infeasible for a human
being to estimate the optimal dosimetry. The model we built
for Tomotherapy cannot only improve planning efficiency, but
can also serve as a quality control tool for dosimetric eval-
uation of clinical plans. This will help the establishment of
a more comprehensive, quantitative and objective QA proce-
dure for complex Tomotherapy planning.
There have been numerous publications to compare the
dosimetry of Tomotherapy with other IMRT techniques.20–23
The aim of this paper is not to compare the dosimetry of To-
motherapy and FG-IMRT. However the models we built for
these modalities from a library of high quality plans can in
fact provide more detailed dosimetric information like DVH
of each structure. Therefore, models can be helpful in choos-
ing an appropriate treatment modality for certain disease sites.
The current clinical trial protocol of RTOG or other organi-
zations normally simplifies the dosimetric requirement with a
few dosimetric parameters. While meeting all of these loosely
sampled DVH points, the overall shape of DVH may be
very different among plans. Therefore, the accurate control of
dosimetry quality of patients under the protocol can be chal-
lenging and even impossible. With the method demonstrated
in this work, our model can produce the anticipated DVHs
of an individual patient case. In this way, the institutions that
participate in the trial can have a clear and comprehensive
dosimetric goal to follow. Consequently the treatment plans
generated by different medical centers may have more uni-
form dosimetric quality, which may lead to more robust data
analysis of clinical trials.
5. CONCLUSIONS
We established a mathematical model to correlate the
anatomical features and dosimetric indexes of OARs of HN
patients in Tomo-IMRT and FG-IMRT plans. The model may
be used for the setup of patient-specific OAR dose sparing
goals and quality control of planning results. The institutional
clinical experience was incorporated into the model which al-
lows the model from one institution to generate a reference
plan for another institution or another IMRT technique.
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